Stange J.P.,Temple University |
Sylvia L.G.,Massachusetts General Hospital |
Da Silva Magalhaes P.V.,UniversidadeFederal Do Rio Grande Do sul |
Miklowitz D.J.,University of California at Los Angeles |
And 7 more authors.
Journal of Clinical Psychiatry | Year: 2013
Objective: Little is known about predictors of recovery from bipolar depression or moderators of treatment response. In the present study, we investigated attributional style (a cognitive pattern of explaining the causes of life events) as a predictor of recovery from episodes of bipolar depression and as a moderator of response to psychotherapy for bipolar depression. Method: 106 depressed outpatients with DSM-IV bipolar I or II disorder who were enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder were randomly assigned to intensive psychotherapy for depression (n = 62) or to collaborative care (n = 44), a minimal psychoeducational intervention. The primary outcome was recovery status at each study visit as measured by the Clinical Monitoring Form. Attributional style was measured at baseline using the Attributional Style Questionnaire. Data were collected between 1998 and 2005. Results: All analyses were by intention to treat. Extreme attributions predicted a lower likelihood of recovery (P < .01; OR = 0.93; 95% CI, 0.88-0.98) and longer time until recovery (P < .01; OR = 0.96; 95% CI, 0.93-0.99), independent of the effects of initial depression severity. Among individuals with more pessimistic attributional styles, higher initial depression severity predicted a lower likelihood of recovery (P = .01; OR = 0.64; 95% CI, 0.45-0.91) and longer time until recovery (P < .001; OR = 0.76; 95% CI, 0.66-0.88). There was no difference in recovery rates between intensive psychotherapy and collaborative care (OR = 0.90; 95% CI, 0.40-2.01) in the full sample. Conclusions: These results suggest that extreme, rigid attributions may be associated with a more severe course of depression and that evaluating attributional style may help clinicians to identify patients who are at risk for experiencing a more severe course of depression. © Copyright 2013 Physicians Postgraduate Press, Inc.'.
de Andrade C.,UniversidadeFederal Do Rio Grande Do sul |
de Araujo Lock G.,Federal University of Rio Grande do Sul |
Pigatto M.C.,UniversidadeFederal Do Rio Grande Do sul |
Haas S.E.,UniversidadeFederal Do Rio Grande Do sul |
And 4 more authors.
Biomedical Chromatography | Year: 2014
A novel LC-MS/MS method was developed for the quantification of vildagliptin in an aqueous matrix. The method was successfully validated, meeting all the requisites of US Food and Drug Administration guide for a bioanalytical method. The developed method presented a limit of quantification of 10ng/mL and the range of concentration achieved was 10-1875ng/mL. The injection volume necessary was only 10μL, and retention time was 4.60min. The mobile phase employed was methanol-ammonium acetate 5mm (95:5). The stability of the drug was evaluated in the different conditions through which the samples passed. A pharmacokinetic experiment was conducted with diabetic male Wistar rats, and the concentration of drug in liver was evaluated through a microdialysis technique. The perfusion fluid employed was ultrapure water. The dose administrated was 50mg/kg and the method allowed the quantification of vildagliptin for more than three half lives, successfully characterizing the pharmacokinetic profile when the developed method was applied. This is the first report on the tissue pharmacokinetics of a DPP-4 inhibitor and could contribute to drug dosage optimization in the future. © 2014 John Wiley & Sons, Ltd.